Patient Home
Welcome to Health Vidya. Discover trusted care and your own health — all in one place.
These highlights do not include all the information needed to use REBYOTA safely and effectively. See full prescribing information for REBYOTA. REBYOTA™ (fecal microbiota, live - jslm) suspension, for rectal use Initial U.S. Approval: 2022
Medication labelWhy this: Advisory · dailymed-prescription
REBYOTA is indicated for the prevention of recurrence of Clostridioides difficile infection (CDI) in individuals 18 years of age and older following antibiotic treatment for recurrent CDI. Limitation of Use: REBYOTA is not indicated for treatment of CDI.
- generic_name
- donor human stool
- product_names
- Donor Human Stool
- ndc
- 55566-9800, 55566-9800-0, 55566-9800-1, 55566-9800-2
- group
- drugs
- license
- us-gov-pd
- attribution
- Courtesy of the National Library of Medicine
- reviewed
- 2026-09-18
- language
- en